Eledon Pharmaceuticals (ELDN) Stock Forecast & Price Target

Eledon Pharmaceuticals Inc. demonstrates promising potential due to the encouraging results of its compound, tegoprubart, which aims to improve graft survival and kidney function in transplant patients compared to standard care. The Phase 2 BESTOW trial results indicate that tegoprubart offers a favorable safety and tolerability profile, showing substantially reduced toxicities compared to tacrolimus, historically used in immunosuppression therapy. Furthermore, the stabilization of kidney function, as reflected by an approximate eGFR of 68 mL/min/1.73m² through 12 months post-transplant in patients using tegoprubart, underscores its therapeutic promise in the transplantation sector.

Eledon Pharmaceuticals Inc. reported a net loss of $17.5 million for the third quarter of 2025, a significant decrease from the net income of $77.0 million in the same quarter of 2024, which was inflated by a one-time non-cash gain. The company’s operating expenses also declined to $19.1 million, primarily due to reduced research and development costs, yet persistent risks associated with the clinical trials, regulatory approval, and commercial success of its lead compound, tegoprubart, cast uncertainty on future financial performance. Additionally, the potential for dilution and challenges related to reimbursement and market penetration further exacerbate the negative outlook for Eledon's stock.